Drug
CTX-471
CTX-471 is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Not yet recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
not_yet_recruiting150%
completed150%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_1
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
NCT03881488
not_yet_recruitingphase_1
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
NCT07392957
Clinical Trials (2)
Showing 2 of 2 trials
NCT03881488Phase 1
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
NCT07392957Phase 1
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2